rss
Ann Rheum Dis 2009;68:1100-1104 doi:10.1136/ard.2008.093690
  • Clinical and epidemiological research

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research

This article has been Unlocked
  1. C Salliot1,
  2. D van der Heijde2
  1. 1
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
  2. 2
    Rheumatology Department, Leiden University Medical Centre, Leiden, The Netherlands
  1. Dr C Salliot, Hôpital Cochin, service de Rhumatologie B, rue du faubourg Saint-Jacques, 75014 Paris, France; carinesalliot{at}gmail.com
  • Accepted 17 November 2008
  • Published Online First 5 December 2008

Abstract

Objective: To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA).

Methods: A search was performed in Medline, Cochrane and EMBASE. Adults with RA who had received MTX monotherapy for more than 2 years were studied.

Results: 88 published studies were included. Over 12 years of treatment, the termination rate of MTX due to toxicity was less than for sulfasalazine, gold, d-penicillamine and higher than for hydroxychloroquine (level of evidence 2a–2b). Long-term use of MTX does not appear to be a risk factor for serious infections, including herpes zoster (2b–4), and could provide a survival benefit by reducing cardiovascular mortality (2b). The prevalence of raised liver enzymes (more than twice the upper limit of normal) is close to 13% of patients; 3.7% of patients stopped MTX permanently owing to liver toxicity (2b). Data on the risk for liver fibrosis/cirrhosis are conflicting: a meta-analysis showed an incidence of fibrosis of 2.7% after 4 years of MTX (2a). However, two other studies on sequential liver biopsies did not show evidence for developing severe damage (2b). Insufficient data are available to fully assess the risk of lymphoma and malignancies, although there is no strong evidence of increased risk (2b–4).

Conclusion: This systematic literature search on MTX monotherapy with relatively low-dose use during at least 2 years shows favourable long-term safety.

Footnotes

  • Additional tables, figure and references are published online only at http://ard.bmj.com/content/vol68/issue7

  • Funding: This work was supported by Abbott with an unrestricted educational grant.

  • Competing interests: None.

This article has been Unlocked

This Article

  1. Free via Creative Commons: CC
  2. Abstract
  3. Full text
  4. PDF
  5. Web only appendix
  6. All versions of this article:
    1. ard.2008.093690v1
    2. 68/7/1100 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.